Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Given Consensus Recommendation of “Hold” by Analysts

Posted by Brian Himes on Aug 14th, 2026

Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN – Get Free Report) has been assigned an average recommendation of “Hold” from the fifteen brokerages that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, six have assigned a hold rating and eight have given a buy rating to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $52.2857.

Several analysts recently issued reports on LEGN shares. Raymond James Financial reissued an “outperform” rating and issued a $58.00 price target on shares of Legend Biotech in a research report on Monday, July 27th. Barclays dropped their price objective on shares of Legend Biotech from $80.00 to $78.00 and set an “overweight” rating on the stock in a research note on Wednesday. TD Cowen reduced their price objective on shares of Legend Biotech from $29.00 to $24.00 and set a “hold” rating for the company in a report on Wednesday. JPMorgan Chase & Co. began coverage on shares of Legend Biotech in a research report on Monday, July 13th. They set a “neutral” rating and a $35.00 target price for the company. Finally, Benchmark reaffirmed a “buy” rating on shares of Legend Biotech in a research report on Tuesday, July 28th.

Read Our Latest Report on LEGN

Insider Transactions at Legend Biotech

In related news, CEO Ying Huang sold 5,566 shares of the stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $14.78, for a total value of $82,265.48. Following the completion of the sale, the chief executive officer directly owned 241,872 shares of the company’s stock, valued at approximately $3,574,868.16. This represents a 2.25% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 0.02% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. Parallel Advisors LLC grew its position in Legend Biotech by 171.9% in the 3rd quarter. Parallel Advisors LLC now owns 1,047 shares of the company’s stock worth $34,000 after purchasing an additional 662 shares in the last quarter. Raymond James Financial Inc. bought a new position in shares of Legend Biotech in the second quarter valued at approximately $78,000. Harvest Fund Management Co. Ltd bought a new position in shares of Legend Biotech in the third quarter valued at approximately $104,000. Clearstead Advisors LLC increased its position in shares of Legend Biotech by 310.7% during the fourth quarter. Clearstead Advisors LLC now owns 3,479 shares of the company’s stock valued at $76,000 after acquiring an additional 2,632 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd lifted its holdings in Legend Biotech by 1,730.3% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,569 shares of the company’s stock worth $78,000 after acquiring an additional 3,374 shares during the period. 70.89% of the stock is owned by institutional investors.

Legend Biotech Stock Performance

Shares of NASDAQ:LEGN opened at $20.27 on Friday. The business’s 50 day simple moving average is $26.10 and its two-hundred day simple moving average is $23.16. The firm has a market cap of $3.76 billion, a P/E ratio of -81.08 and a beta of 0.37. Legend Biotech has a 52-week low of $16.24 and a 52-week high of $38.35.

Legend Biotech (NASDAQ:LEGN – Get Free Report) last released its quarterly earnings data on Tuesday, August 11th. The company reported $0.09 EPS for the quarter, beating the consensus estimate of $0.07 by $0.02. Legend Biotech had a negative return on equity of 9.23% and a negative net margin of 7.21%.The firm had revenue of $387.50 million during the quarter, compared to the consensus estimate of $355.96 million. During the same quarter in the previous year, the company posted $0.03 earnings per share. The company’s quarterly revenue was up 51.9% on a year-over-year basis. On average, equities analysts forecast that Legend Biotech will post -0.01 earnings per share for the current fiscal year.

Legend Biotech News Summary

Here are the key news stories impacting Legend Biotech this week:

Positive Sentiment: Quarterly results exceeded expectations: Legend reported second-quarter EPS of $0.09 versus the $0.07 consensus, while revenue reached $387.5 million, ahead of estimates of $356.0 million and up 51.9% year over year. Reports said shares rose following the earnings release, supporting the view that demand for Carvykti and the company’s cell-therapy business remains strong. Legend Biotech Reports Second Quarter 2026 Results and Recent Highlights
Positive Sentiment: Morgan Stanley issued a Buy rating: The bullish recommendation provides a counterweight to recent downgrades and may signal confidence in Legend’s commercial outlook and longer-term pipeline. Legend Biotech Receives a Buy from Morgan Stanley
Positive Sentiment: Pipeline assets are becoming more important: Commentary highlighted Legend’s developing pipeline as a potential source of future growth beyond Carvykti, although these programs remain longer-term catalysts. Legend’s Pipeline Is Starting To Matter
Neutral Sentiment: Analyst targets remain widely dispersed: RBC maintained an Outperform rating with a $58 target, while Oppenheimer retained Market Perform at $40. A broader analyst compilation cited an average target of $55.29, indicating substantial perceived upside but also high uncertainty.
Negative Sentiment: Leadership and competitive risks are pressuring sentiment: Oppenheimer downgraded Legend following the CEO’s departure, warning that increased competition could pressure the business. The former chief executive’s move to lead new biotech venture K2 Therapeutics may reinforce concerns about management continuity and talent retention. Legend Biotech Could See Pressures From Competition, CEO Transition, Oppenheimer Says
Negative Sentiment: Several firms cut their targets: TD Cowen lowered its target to $24 and assigned Hold, while Oppenheimer reduced its target from $75 to $40. Although both targets remain above the current trading level, the magnitude of the cuts highlights deteriorating near-term expectations. Legend Biotech Downgraded at Oppenheimer

Legend Biotech Company Profile

(Get Free Report)

Legend Biotech (NASDAQ: LEGN) is a commercial-stage biopharmaceutical company specializing in the development and commercialization of chimeric antigen receptor T-cell (CAR-T) therapies for oncology. Headquartered in Somerset, New Jersey, with research and development operations in Shanghai, the company leverages a global infrastructure to advance innovative cellular therapies. Legend Biotech pursues a strategy of strategic collaboration to extend its reach, most notably through its partnership with Janssen Biotech, a subsidiary of Johnson & Johnson.

The company’s lead asset, ciltacabtagene autoleucel (commercially marketed as Carvykti), is a B-cell maturation antigen (BCMA)–directed CAR-T therapy for the treatment of relapsed or refractory multiple myeloma.